January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
Juncell Therapeutics
Juncell is a clinical-stage biotech focused on TIL (tumor-infiltrating lymphocyte) cell therapy for solid tumors. We have improved the safety profile and affordability of TIL therapy without compromising efficacy. We have filed for HKEX IPO.